In addition to a diabetes diagnosis, people with a history of smoking and who have specific comorbidities, such as heart disease, liver disease, and chronic lower respiratory disease, are at increased risk of poorer COVID-19 outcomes.
The Endocrine Society is calling for immediate action by policymakers to address the underlying factors responsible for the rising cost of insulin, a life-saving drug taken by 7.4 million people in the United States.
The risk of coronary heart disease in childhood-onset type 1 diabetes is currently predicted to some extent by focusing on conventional risk factors, including hemoglobin A1C and diabetes duration, but that is hardly sufficient in predicting CHD later in life, researchers report.
Diabetic ketoacidosis has been found to be more prevalent among Black patients with type 1 diabetes and COVID-19, shows a new study. The condition typically disproportionately affects Black and Hispanic patients.
Celiac disease is known to be associated with depression and anxiety in adults with type 1 diabetes and celiac disease. In this study, researchers examine the theory in adolescents with T1D and celiac disease.
A team of investigators conducted a large retrospective, cohort study to assess whether a longitudinal link exists between H pylori infection and the risk of developing dyslipidemia.
Fasting glucose levels and glycemic fluctuations have been found to be independently associated with poor prognosis in adults hospitalized for COVID-19—regardless of diabetes status.
Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
A low-cost, group-delivered lifestyle intervention is associated with a significantly lower risk for progression to type 2 diabetes among high-risk individuals.
Investigators sought to determine whether younger age at diagnosis, female sex, and higher weight z score and HbA1c are risk factors for C-peptide decline after new onset of pediatric type 1 diabetes.
The study goal was to determine whether real-time continuous glucose monitoring up to 24 months is beneficial, particularly in persons living with impaired awareness of hypoglycemia.
